Why methylation is not a marker predictive of response to hypomethylating agents.
about
Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiaClinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.Digging deep into "dirty" drugs - modulation of the methylation machinery.The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia.BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine.Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI-110) in Myeloid Malignancies.Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing.MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine.
P2860
Q26801573-11594E8F-9771-4780-8F49-BD5F57532EE6Q28084813-DEC4CD23-8E20-406E-88B8-21A4260CBB77Q35900361-053D2D26-7F1F-49BB-BF0C-B240AFECA42CQ36523796-F28A194A-EAD9-4C64-9FDB-3A9FFE28D105Q38570399-2A01AD07-054B-4109-B901-81BE122CD264Q38687894-76253A74-9B67-49B2-AF58-CFF00779DE09Q40896172-546268EC-B0E4-4ECF-913C-828E6200429DQ42362036-9A9E0EED-D03A-4951-965C-3B84E1F533F8Q42362055-A74EF8A1-525E-4C6C-83A6-D1F43331AD80Q42621671-3725AE97-24BA-483F-B283-4B5DD1C63210Q47130430-2D82A5FA-3DFA-4233-BF7A-50AA47B262E5Q48181306-90DB5B6F-F65E-4AE6-B523-ECF311F1BD04
P2860
Why methylation is not a marker predictive of response to hypomethylating agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Why methylation is not a marker predictive of response to hypomethylating agents.
@en
Why methylation is not a marker predictive of response to hypomethylating agents.
@nl
type
label
Why methylation is not a marker predictive of response to hypomethylating agents.
@en
Why methylation is not a marker predictive of response to hypomethylating agents.
@nl
prefLabel
Why methylation is not a marker predictive of response to hypomethylating agents.
@en
Why methylation is not a marker predictive of response to hypomethylating agents.
@nl
P2860
P50
P1433
P1476
Why methylation is not a marker predictive of response to hypomethylating agents
@en
P2093
Francesco Guidi
P2860
P304
P356
10.3324/HAEMATOL.2013.099549
P50
P577
2014-04-01T00:00:00Z